A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Phase 3CompletedNCT00523913

GlaxoSmithKline70 enrolled

Overview

This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

rosiglitazoneDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Patients with type 2 diabetes mellitus managed by diet therapy or one antidiabetic agent (sulfonylurea or alpha glucosidase inhibitor) will be candidates for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function. Exclusion Criteria: \- Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.

Locations (1)

GSK Investigational Site

Outcomes

Primary Outcomes

The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated.

Time frame: 52 Weeks

Secondary Outcomes

The efficacy profile (HbA1c, FPG and Insulin) of BRL49653C administered for 52 weeks will be evaluated.

Time frame: 52 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.